Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Teishima, Jun; Matsubara, Akio

doi:10.1111/iju.13592

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of tyrosine kinase inhibitors and immunotherapies has remarkably improved the survival of mRCC patients. [1][2][3][4][5][6][7][8][9][10][11][12] Randomized studies suggested the efficacy of first-line nivolumab plus ipilimumab in patients belonging to the intermediate-and poor-risk groups of the IMDC. [13][14][15] However, the efficacy and safety of the first-line nivolumab plus ipilimumab for mRCC patients need to be validated in actual practice, 14 and CheckMate 214 trial only enrolled a limited number of Japanese patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study

Tanaka¹,

Hatakeyama²,

Numakura³

et al. 2020

Int J of Urology

View full text Add to dashboard Cite

To investigate the efficacy and safety of first-line nivolumab plus ipilimumab for patients treated with metastatic renal cell carcinoma. Methods: We retrospectively evaluated 52 metastatic renal cell carcinoma patients who were treated with nivolumab plus ipilimumab between August 2015 and January 2020. Data on patient characteristics, treatment parameters and adverse events were obtained. Oncological outcomes were assessed according to the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model. Furthermore, differences in treatment parameters between patients with objective response (responders) and non-responders were compared. Results: The median age and follow-up periods were 69 years and 8.2 months, respectively. The 1-year progression-free survival and overall survival rates were 55% and 75%, respectively. The objective response rate was 39%, and it was significantly different between the International Metastatic Renal Cell Carcinoma Database Consortium intermediate-and poor-risk groups (52% vs 24%). We observed 36 (69%) any immunerelated adverse events, and 19 (37%) severe immune-related adverse events (grades III-V). The International Metastatic Renal Cell Carcinoma Database Consortium poor-risk group and higher value of initial C-reactive protein (≥1.0 mg/dL) were significantly associated with non-responders. Patients with two factors (the International Metastatic Renal Cell Carcinoma Database Consortium poor-risk group plus C-reactive protein ≥1.0 mg/dL) had a significantly poor overall survival than those with none or a single factor. Conclusions: In our experience, treatment response to nivolumab plus ipilimumab is comparable with that of the CheckMate 214 clinical trial, but the incidence of treatmentrelated adverse events is lower. The International Metastatic Renal Cell Carcinoma Database Consortium poor-risk group and initial C-reactive protein value might have a prognostic value for poor survival.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The introduction of tyrosine kinase inhibitors and immunotherapies has remarkably improved the survival of mRCC patients 1–12 . Randomized studies suggested the efficacy of first‐line nivolumab plus ipilimumab in patients belonging to the intermediate‐ and poor‐risk groups of the IMDC 13–15 .…”

Section: Introductionmentioning

confidence: 99%